Fw: Mesothelin-related predictive and prognostic factors in malignant mesothelioma: A nested case-control study.

----- Forwarded Message ----
From: HubMed - mesothelioma diagnosis <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Wednesday, February 20, 2008 3:40:20 AM
Subject: Mesothelin-related predictive and prognostic factors in malignant mesothelioma: A nested case-control study.

[1]Lung Cancer. 2008 Feb 15;
Roe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P, Nilsen TI, Robinson B, Kjaerheim K

Soluble mesothelin-related protein (SMRP) in serum is potentially a sensitive marker of malignant mesothelioma (MM) diagnosis and progression, and may be useful as screening marker. Mesothelin expression in tumors is regarded as a sensitive marker for diagnosis and disease progression, and is a candidate prognostic marker. Levels of SMRP, CA125 and CYFRA 21-1 in pre-diagnostic (1-30 years) serum samples from 47 mesothelioma cases and 141 matched controls were analysed. Mesothelin expression in tumors was assessed. The association between biomarker level and mesothelioma risk and survival was analysed, adjusting for asbestos exposure. Survival related to tumor mesothelin expression, age, sex, histological type, location, asbestos exposure and pre-clinical SMRP was analysed. There was no significant association between biomarker levels and mesothelioma risk when analysed as continuous variables or as tertiles. Biomarker levels /=20 years before diagnosis were not significantly associated to mesothelioma risk. Mesothelin expressed in >50% of tumor cells was seen in 36 of 47 (77%) tumors. Mesothelin expression in 65 years) was an independent negative prognostic factor that was related to both mesothelin expression and asbestos exposure. Mesothelioma of the epithelial type of the peritoneum had a significantly longer survival than epithelial type in pleura and was also related to mesothelin expression.



___
Source: http://www.hubmed.org/display.cgi?uids=18281122
--
To unsubscribe from [2]this feed, click [3]here
To manage other subscriptions, click [4]here
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

---

Never miss a thing. Make Yahoo your homepage.

Fwd: [Combination of Operation, Chemotherapy and Radiation for AFP Producing Gastric Cancer - A Case Report.]

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Wed, Feb 20, 2008 at 4:02 AM
Subject: [Combination of Operation, Chemotherapy and Radiation for AFP Producing Gastric Cancer - A Case Report.]
To: mesothelioma77@gmail.com


[1]Gan To Kagaku Ryoho. 2008 Feb; 35(2): 299-301
Nakamura H, Nakai S, Morifuji 2 M, Fujimoto M, Miyamoto K, Yokoyama Y

We report a case of AFP producing gastric cancer after a combination of operation, chemotherapy and radiation. A 70-year-old man was admitted complaining of abdominal fullness. He was diagnosed as having type 3 advanced gastric cancer with multiple lymph node metastasis, including No. 8p lymph node, by endoscopy and computed tomography. Distal gastrectomy and D2 lymph node dissection were performed after chemotherapy using S-1, low-dose CDDP and CPT-11. Histopathological study showed moderately differentiated adenocarcinoma, and immunohistochemical study revealed a few AFP-positive tumor cells. Postoperatively, radiation (50 Gy) was performed for paraaortic lymph node metastasis and right hepatic lobectomy for liver metastasis. However, about 2 months after hepatic lobectomy, liver metastasis was diagnosed again by computed tomography, and radiation (30 Gy) was performed. He died 13 months after first surgery.



___
Source: http://www.hubmed.org/display.cgi?uids=18281769
--
To unsubscribe from [2]this feed, click [3]here
To manage other subscriptions, click [4]here
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: [A Case of Advanced Gastric Cancer Effectively Treated with Combination of Weekly Paclitaxel and Hepatic Arterial Infusion of 5-FU/LV.]

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Wed, Feb 20, 2008 at 4:02 AM
Subject: [A Case of Advanced Gastric Cancer Effectively Treated with Combination of Weekly Paclitaxel and Hepatic Arterial Infusion of 5-FU/LV.]
To: mesothelioma77@gmail.com


[1]Gan To Kagaku Ryoho. 2008 Feb; 35(2): 303-306
Oida Y, Motojuku M, Morikawa G, Mukai M, Imaizumi T, Makuuchi H

The patient was a 66-year-old woman who underwent upper gastrointestinal endoscopy as part of a detailed examination because of loss of appetite and anemia, and type 2 gastric cancer was detected on the greater curvature in the pyloricarea. Abdominal ultrasonography and CT revealed lymph node enlargement around the pyloricarea and multiple liver metastases in both lobes of the liver. Curative resection was judged to be impossible, and oral S-1 therapy was started. However, no efficacy was observed even after the completion of three courses, and especially because of the rapid increase in the size of the liver metastases, treatment was switched to combination therapy consisting of a continuous hepaticartery infusion of 5-FU+Leucovorin (day 1-7) and weekly PTX for 3 consecutive weeks (day 8, 15, 22) followed by a 1-week rest. The tumor marker levels decreased rapidly, and at the end of 4 courses marked regression of the primary tumor and lymph node metastases as well as of the metastaticfoc i in the liver was observed. Adverse events have been mild, and at present, 6 months after the switch in treatment, good QOL has been maintained, and treatment is continuing. This method appears to be an effective treatment strategy for unresectable advanced gastric cancer complicated by liver metastasis.



___
Source: http://www.hubmed.org/display.cgi?uids=18281770
--
To unsubscribe from [2]this feed, click [3]here
To manage other subscriptions, click [4]here
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: [A Fatal Case of Meningeal Carcinomatosis in a Stage IV Gastric Cancer Patient Who Responded to Multi-Line Chemotherapy.]

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Wed, Feb 20, 2008 at 4:02 AM
Subject: [A Fatal Case of Meningeal Carcinomatosis in a Stage IV Gastric Cancer Patient Who Responded to Multi-Line Chemotherapy.]
To: mesothelioma77@gmail.com


[1]Gan To Kagaku Ryoho. 2008 Feb; 35(2): 307-310
Yagi K, Nishioka M, Satoh H, Soga T, Tezuka M, Tezuka A

A 60-year-oldman was diagnosedwith Stage IV gastric cancer with pyloric stenosis, peritoneal dissemination and multiple bone metastasis. One course of low dose CDDP and5-FU, and3 courses of S-1 and CDDP were carried out. Although a partial response was obtained, a large amount of ascites appeared again. As a third-line chemotherapy for this patient, PTX (60-100 mg/body) was administered to the peritoneal cavity on day 1 and 14, and S-1 (80 mg/body/ day) was given orally for 2 weeks followed by a 14-day rest period. The ascites had completely disappeared after 1 course of the combinedchemotherapy. As a fourth-line chemotherapy, combination chemotherapy of biweekly infused PTX and daily oral S-1 was started, because the primary gastric lesion was increased. Subsequently, various neurological symptoms rapidly appeared, including dizziness, hypertension, and convulsion. Meningeal carcinomatosis was diagnosed by an examination of cerebrospinal fluid, and he died of disease rapid progression.



___
Source: http://www.hubmed.org/display.cgi?uids=18281771
--
To unsubscribe from [2]this feed, click [3]here
To manage other subscriptions, click [4]here
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: [A Case of Sigmoid Colon Cancer with Multiple Liver Metastases Responding to S-1.]

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Wed, Feb 20, 2008 at 4:02 AM
Subject: [A Case of Sigmoid Colon Cancer with Multiple Liver Metastases Responding to S-1.]
To: mesothelioma77@gmail.com


[1]Gan To Kagaku Ryoho. 2008 Feb; 35(2): 315-317
Maruyama T, Takagaki T, Hara K, Ohkohchi N

A 74-year-old woman was referred to our hospital with complaints of constipation and abdominal distention caused by a sigmoid colon tumor. After examination, she was diagnosed as sigmoid colon cancer with multiple liver metastases. To prevent bowel obstruction, a sigmoid colon resection was performed. On postoperative days 15, S-1 was started, and she was discharged on postoperative day 26. Each course consisted of daily oral administration S-1 for 4 weeks followed by 2 drug-free weeks. However, because of grade 2 anorexia in the 1st course, the treatment plan was changed to administration for 2 weeks and withdrawal for 1 week. After 7courses of treatment, computed tomography revealed that the liver metastases were remarkably reduced. Although she experienced an adverse event involving a cutaneous symptom of grade 2, the treatment was continued under ambulatory management. After eight courses, elevation of tumor marker and metastasis at the right femur were found, and she died of the cancer 12 months after the operation. S-1 is expected to be an effective agent for the treatment of advanced colorectal cancer.



___
Source: http://www.hubmed.org/display.cgi?uids=18281773
--
To unsubscribe from [2]this feed, click [3]here
To manage other subscriptions, click [4]here
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: $1,500 per mesothelioma lead

----- Forwarded Message ----
From: Search for mesothelioma diagnosis <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Sunday, February 17, 2008 4:55:39 PM
Subject: $1,500 per mesothelioma lead

According to a website maintained by MediaBids , an online advertising broker, the Boston law firm of James Sokolove as of recently was offering $1,500 for every mesothelioma "lead" that publishers could bring ...

Sun, 17 Feb 2008 05:00:05 GMT

___
Source: http://www.overlawyered.com/2008/02/1500_per_mesothelioma_lead.html
--
 

---

Never miss a thing. Make Yahoo your homepage.

Fwd: Points of DISORDER

---------- Forwarded message ----------
From: Live Search News: asbestos cancer <rssfwd@rssfwd.com>
Date: Feb 20, 2008 4:02 AM
Subject: Points of DISORDER
To: mesothelioma77@gmail.com


Daily Mirror - On industrial Tyneside scarring of the lungs from heavy exposure to asbestos is a major concern. In leafy Tunbridge Wells they ... in seven diagnosed with pleural plaques is sentenced to an agonising death, destined to perish of the terrible lung cancer ...

Wed, 20 Feb 2008 05:25:00 GMT

___
Source: http://www.mirror.co.uk/news/topstories/2008/02/20/points-of-disorder-89520-20325045/
--
 

Fwd: [A Case of Long-Term Survival of Postoperative Brain Metastasis of Small Cell Lung Cancer Effectively Treated with Chemotherapy, Whole Brain Radiotherapy and Stereotactic Radiosurgery.]

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Feb 20, 2008 4:02 AM
Subject: [A Case of Long-Term Survival of Postoperative Brain Metastasis of Small Cell Lung Cancer Effectively Treated with Chemotherapy, Whole Brain Radiotherapy and Stereotactic Radiosurgery.]
To: mesothelioma77@gmail.com


[1]Gan To Kagaku Ryoho. 2008 Feb; 35(2): 331-334
Yohena T, Kuniyoshi M, Teruya T, Kawasaki H, Teruya J, Kawabata T, Ohta M, Ishikawa K, Oshiro Y, Chinen T, Uehara T, Hirayasu T, Ogawa K, Samura H

A 63-year-old woman underwent right upper lobectomy for small cell carcinoma. She received a total of 2courses of carboplatin and etoposide infusion as adjuvant therapy. One year after the operation, because of elevated serum Pro GRP levels and a metastatic brain tumor revealed by CT, 4 courses of IP therapy (irinotecan 60 mg/m(2), day 1, 8, 15 and cisplatin 60 mg/m(2), day 1, every 4 weeks) and whole brain radiotherapy (2Gy f, 5 f/week, total 40 Gy) were given. A complete response was obtained, but a tumor relapse occurred ten months after the last chemotherapy. We then performed a stereotactic radiosurgery (marginal dose: 22 Gy, maximum dose 44 Gy), and one month later MRI showed the tumor had shrunk markedly. FDG-PET showed no intensive uptake, suggesting that there was no remaining viable tumor. No severe side effects were observed during these treatments. Currently, the patient has been alive with good performance status and no signs of relapse.



___
Source: http://www.hubmed.org/display.cgi?uids=18281777
--
 

Fwd: [Two Cases with Recurrent Non-Small Cell Lung Cancer Successfully Treated with Cisplatin and S-1.]

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Feb 20, 2008 4:02 AM
Subject: [Two Cases with Recurrent Non-Small Cell Lung Cancer Successfully Treated with Cisplatin and S-1.]
To: mesothelioma77@gmail.com


[1]Gan To Kagaku Ryoho. 2008 Feb; 35(2): 327-330
Hirose T, Hosaka T, Nakashima M, Sugiyama T, Ishida H, Yamaoka T, Okuda K, Adachi M

We report two cases with recurrent non-small cell lung cancer (NSCLC) successfully treated with cisplatin and S-1 after multiple chemotherapy. A 64-year-old woman was diagnosed with adenocarcinoma, yield-T4N2M1, stage IV. She was treated with cisplatin 60 mg/m(2) (day 8) and S-1 80 mg/m(2) (days 1-21) as sixth-line chemotherapy after treatment with paclitaxel and irinotecan, cisplatin and gemcitabine, docetaxel, gefitinib, and vinorelbine. Chest computed tomography (CT) showed partial response of recurrent tumors. Another woman (56 years old) was diagnosed with adenocarcinoma, yield-T0N1M1, stage IV. She was also treated with cisplatin and S-1 as fourth-line chemotherapy after treatment with nedaplatin and gemcitabine, docetaxel and irinotecan, and gefitinib. Chest CT showed a partial response of recurrent tumors. Additionally, we retrospectively reviewed 10 cases with recurrent NSCLC treated with cisplatin and S-1 during the same period. Grade 3 to 4 hematologic toxicity included neutropenia in 30% of these 10 patients, thrombocytopenia in 20%, and anemia in 60%. Grade 3 non-hematologic toxicity included hyperglycemia and hyponatremia in 20% of the 10 patients. All side effects were manageable and there was no case of treatment-related death. Cisplatin combined with S-1 could be an option for recurrent NSCLC.



___
Source: http://www.hubmed.org/display.cgi?uids=18281776
--
 

Fwd: [Remarkably Reduced Tumor Marker SCC Levels by Combined Chemotherapy of Paclitaxel and S-1 in Two Cases of Advanced Cervical Cancer.]

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Feb 20, 2008 4:02 AM
Subject: [Remarkably Reduced Tumor Marker SCC Levels by Combined Chemotherapy of Paclitaxel and S-1 in Two Cases of Advanced Cervical Cancer.]
To: mesothelioma77@gmail.com


[1]Gan To Kagaku Ryoho. 2008 Feb; 35(2): 335-337
Takagi K, Kougo H, Aoyagi Y, Yonehara T, Minobe S, Azuma M, Yamaguchi T

Case 1: A-35-year-old woman was diagnosed as cervical cancer Stage IIIb. When admitted to the hospital, her tumor marker SCC level was 50 ng/mL. Concurrent chemoradiation therapy was started on November, 2005. The SCC level was reduced by 0.9 ng/mL in February, 2006. In April, tumor recurrence was found by PET, and chemotherapy was restarted, but the SCC level was increased. In September, paclitaxel/S-1therapy was performed, and the tumor mark- ers were again reduced remarkably (SCC 9.8--> 1.3 ng/mL). Case 2: A-78-year-old woman was diagnosed as cervical cancer Stage IIIb. In August, 2004, concurrent chemoradiation therapy was started, and tumor markers were reduced (SCC 25.4--> 1.8 ng/mL). However, tumor markers were increased soon after the therapy. Chemotherapy was started, but it could not be maintained because of the side effects. In April, 2006, paclitaxel/S-1therapy was performed, and the tumor markers were reduced remarkably (SCC 120--> 10 ng/mL). However, that therapy could also not be maintained because of the side effect. In July, she died of the cancer.



___
Source: http://www.hubmed.org/display.cgi?uids=18281778
--